MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-03-2025
Castle Biosciences Operating Cycle 2011-2026 | CSTL
Annual Operating Cycle Castle Biosciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 97.9 | 99.7 | 88.5 | 107 | 158 | 165 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 165 | 88.5 | 119 |
Quarterly Operating Cycle Castle Biosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 97.4 | 96.9 | 97.5 | - | 93.8 | 95.7 | 102 | - | 98.6 | 97.6 | 93.7 | - | 92.9 | 89.6 | 96.7 | - | 116 | 119 | 122 | 67.3 | 158 | 186 | 138 | 75.8 | 157 | 181 | 200 | 96.5 | 357 | 169 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 357 | 67.3 | 127 |
Operating Cycle of other stocks in the Diagnostics research industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
170 | - | -6.23 % | $ 30.6 M |  Germany |
|
Biodesix
BDSX
|
41.7 | $ 18.66 | -0.64 % | $ 2.42 B |  USA |
 |
BioNano Genomics
BNGO
|
329 | $ 1.1 | -1.79 % | $ 1.4 M | USA |
 |
Bioventus
BVS
|
259 | $ 8.23 | -2.14 % | $ 548 M | USA |
|
Akumin
AKU
|
57.4 | - | -17.87 % | $ 25.9 M |  Canada |
 |
CareDx, Inc
CDNA
|
51.5 | $ 17.27 | -3.47 % | $ 920 M | USA |
 |
Aspira Women's Health
AWH
|
73.8 | - | -6.19 % | $ 10.5 M | USA |
 |
Charles River Laboratories International
CRL
|
65 | $ 173.17 | -0.73 % | $ 8.58 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
54.2 | $ 199.02 | -0.1 % | $ 22.1 B | USA |
 |
Danaher Corporation
DHR
|
143 | $ 195.59 | 0.01 % | $ 139 B | USA |
 |
DarioHealth Corp.
DRIO
|
251 | $ 9.54 | -1.65 % | $ 271 M |  Israel |
 |
DexCom
DXCM
|
202 | $ 67.42 | -1.0 % | $ 26.3 B | USA |
 |
Exact Sciences Corporation
EXAS
|
91.7 | $ 103.45 | -0.05 % | $ 19.5 B | USA |
 |
Fulgent Genetics
FLGT
|
77.4 | $ 14.49 | -0.96 % | $ 438 M | USA |
 |
Co-Diagnostics
CODX
|
405 | - | - | $ 79.8 M | USA |
 |
Guardant Health
GH
|
128 | $ 88.77 | -2.67 % | $ 11.1 B | USA |
 |
Accelerate Diagnostics
AXDX
|
489 | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
202 | - | - | $ 399 M |  China |
 |
DermTech
DMTK
|
114 | - | -11.32 % | $ 2.94 M | USA |
 |
Genetic Technologies Limited
GENE
|
11.8 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
185 | - | 0.12 % | $ 80.1 M | China |
 |
ICON Public Limited Company
ICLR
|
68.5 | $ 106.98 | -0.21 % | $ 8.82 B |  Irlanda |
 |
Interpace Biosciences
IDXG
|
79.2 | $ 1.72 | -1.15 % | $ 7.55 M | USA |
 |
IDEXX Laboratories
IDXX
|
128 | $ 597.79 | -1.75 % | $ 48.1 B | USA |
 |
Illumina
ILMN
|
198 | $ 123.01 | -1.29 % | $ 19.6 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.22 K | - | - | $ 10.7 B | USA |
 |
IQVIA Holdings
IQV
|
73.9 | $ 177.45 | 1.69 % | $ 30.5 B | USA |
 |
Anixa Biosciences
ANIX
|
275 | $ 2.9 | 1.75 % | $ 94.1 K | USA |
 |
Lantheus Holdings
LNTH
|
121 | $ 77.95 | 7.43 % | $ 5.26 B | USA |
 |
Biocept
BIOC
|
134 | - | -13.05 % | $ 7.29 M | USA |
 |
Medpace Holdings
MEDP
|
50.4 | $ 476.62 | 1.28 % | $ 13.7 B | USA |
 |
Mettler-Toledo International
MTD
|
66.4 | $ 1 212.99 | 0.28 % | $ 25 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
95.1 | $ 4.79 | -7.09 % | $ 444 M | USA |
 |
ENDRA Life Sciences
NDRA
|
412 | $ 3.45 | 1.77 % | $ 1.85 M | USA |
 |
NeoGenomics
NEO
|
102 | $ 8.61 | -3.91 % | $ 1.1 B | USA |
 |
Neogen Corporation
NEOG
|
213 | $ 9.52 | -1.91 % | $ 2.06 B | USA |
 |
National Research Corporation
NRC
|
29.4 | $ 15.5 | 6.24 % | $ 347 M | USA |
 |
Natera
NTRA
|
81.5 | $ 200.05 | 0.97 % | $ 19.7 B | USA |
 |
Heska Corporation
HSKA
|
177 | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
216 | - | -20.0 % | $ 1.06 M | USA |
 |
OPKO Health
OPK
|
285 | $ 1.2 | 1.69 % | $ 833 M | USA |
 |
Pacific Biosciences of California
PACB
|
244 | $ 1.33 | -3.99 % | $ 399 M | USA |
 |
Precipio
PRPO
|
49.8 | $ 26.06 | -1.79 % | $ 33.8 M | USA |
 |
Personalis
PSNL
|
55.8 | $ 7.74 | -1.28 % | $ 459 M | USA |
 |
RadNet
RDNT
|
34.5 | $ 62.21 | 2.51 % | $ 4.68 B | USA |